Market Research Logo

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • The report provides overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Snapshot
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Overview
Key Information
Key Facts
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Research and Development Overview
Key Therapeutic Areas
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products Glance
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
IND/CTA Filed Products/Combination Treatment Modalities
Preclinical Products/Combination Treatment Modalities
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products
Unknown Products/Combination Treatment Modalities
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Drug Profiles
aminolevulinic acid hydrochloride
Product Description
Mechanism of Action
R&D Progress
Hitenercept
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis
Product Description
Mechanism of Action
R&D Progress
T-0001
Product Description
Mechanism of Action
R&D Progress
vincristine sulfate
Product Description
Mechanism of Action
R&D Progress
bevacizumab biosimilar
Product Description
Mechanism of Action
R&D Progress
Fderceptin
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugate to Target CD30 for Solid Tumor
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis
Product Description
Mechanism of Action
R&D Progress
paclitaxel
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar
Product Description
Mechanism of Action
R&D Progress
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Analysis
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Target
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Dormant Projects
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Nifeviroc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Information
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Facts
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Phase II, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Phase I, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - IND/CTA Filed, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Preclinical, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Unknown, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Subsidiaries
List of Figures
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report